Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of pharmaceutical contractor Parexel
So what: Fiscal second-quarter results were decent with revenue rising to $364 million and net income increasing to $16.8 million, but investors were focused on the outlook for fiscal 2011. The company now expects earnings per share of $1.18 to $1.24, down from prior estimates of $1.23 to $1.31 per share.
Now what: Partnerships with Merck
Interested in more info on Parexel? Add it to your watchlist.